1. Noncellular screening for the discovery of protein–protein interaction modulators
- Author
-
Anne Sophie Voisin-Chiret, Marie Jouanne, Charline Kieffer, Jean Pierre Jourdan, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Service de Pharmacie [CHU Caen], CHU Caen, and Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)
- Subjects
Pharmacology ,0303 health sciences ,Computer science ,[SDV]Life Sciences [q-bio] ,Proteins ,Computational biology ,01 natural sciences ,Small molecule ,High-Throughput Screening Assays ,3. Good health ,0104 chemical sciences ,Protein–protein interaction ,010404 medicinal & biomolecular chemistry ,03 medical and health sciences ,Protein Interaction Mapping ,Drug Discovery ,Protein Binding ,030304 developmental biology - Abstract
Protein-protein interactions (PPIs) constitute many potential therapeutic targets for the discovery of new drugs. Given their specificity, PPIs are more challenging to target than other ligands. Thus, finding the best screening process can be difficult. Moreover, PPIs often have no direct accessible activity readout. Therefore, it can be unclear which test to choose for the screening of small molecules targeting PPIs. Given that noncellular assays are the most suitable both as first screening assays and for high-throughput screening (HTS), here we focus on noncellular screening assays. For each assay, we discuss the principles and advantages/drawbacks and provide a recent example. We also highlight the crucial parameters to take into account to select the most suitable assays to screen PPI modulators.
- Published
- 2020